FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:975-976 August 28, 2008 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Sunitinib is an oral, multitargeted kinase that blocks the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and stem-cell factor (c-kit). Sunitinib was approved in 2006 for the treatment of advanced renal-cell carcinoma and gastrointestinal stromal tumors. In clinical trials, dermatologic adverse effects included the acral syndrome (the hand–foot syndrome), seborrheic dermatitis-like eruption, rash, skin discoloration, and hair-color changes, with a prevalence of less than 15%.¹ From October 2005 to June 2007, a total of 40 patients with renal-cell carcinoma, included in a prospective clinical trial and expanded-access program with sunitinib (50 mg daily . . . [Full Text of this Article]

This article has been cited by other articles:

• Lee, S. L. C., Rouhi, P., Jensen, L. D., Zhang, D., Ji, H., Hauptmann, G., Ingham, P., Cao, Y. (2009). Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. USA 106: 19485-19490 [Abstract] [Full Text]